nodes	percent_of_prediction	percent_of_DWPC	metapath
Fulvestrant—breast cancer—ovarian cancer	0.582	1	CtDrD
Fulvestrant—ESR1—ovarian cancer	0.247	1	CbGaD
Fulvestrant—ESR2—ovarian follicle—ovarian cancer	0.00671	0.14	CbGeAlD
Fulvestrant—ESR1—ovarian follicle—ovarian cancer	0.00459	0.0959	CbGeAlD
Fulvestrant—ESR2—oviduct—ovarian cancer	0.00295	0.0615	CbGeAlD
Fulvestrant—ESR1—oviduct—ovarian cancer	0.00202	0.0422	CbGeAlD
Fulvestrant—EPHX2—myometrium—ovarian cancer	0.00179	0.0375	CbGeAlD
Fulvestrant—ESRRA—myometrium—ovarian cancer	0.00157	0.0328	CbGeAlD
Fulvestrant—ESRRA—uterine cervix—ovarian cancer	0.00122	0.0255	CbGeAlD
Fulvestrant—NR1H4—female reproductive system—ovarian cancer	0.0012	0.025	CbGeAlD
Fulvestrant—ESRRA—decidua—ovarian cancer	0.00116	0.0243	CbGeAlD
Fulvestrant—EPHX2—uterus—ovarian cancer	0.00116	0.0243	CbGeAlD
Fulvestrant—ESRRA—endometrium—ovarian cancer	0.00111	0.0231	CbGeAlD
Fulvestrant—NR1H4—female gonad—ovarian cancer	0.00109	0.0227	CbGeAlD
Fulvestrant—ESRRA—uterus—ovarian cancer	0.00102	0.0213	CbGeAlD
Fulvestrant—EPHX2—female gonad—ovarian cancer	0.000952	0.0199	CbGeAlD
Fulvestrant—EPHX2—vagina—ovarian cancer	0.000946	0.0198	CbGeAlD
Fulvestrant—ESRRA—female reproductive system—ovarian cancer	0.000916	0.0191	CbGeAlD
Fulvestrant—ESRRA—bone marrow—ovarian cancer	0.000865	0.0181	CbGeAlD
Fulvestrant—EPHX2—testis—ovarian cancer	0.000844	0.0176	CbGeAlD
Fulvestrant—ESRRA—female gonad—ovarian cancer	0.000834	0.0174	CbGeAlD
Fulvestrant—ESRRA—vagina—ovarian cancer	0.000829	0.0173	CbGeAlD
Fulvestrant—ESR2—epithelium—ovarian cancer	0.00074	0.0155	CbGeAlD
Fulvestrant—ESRRA—testis—ovarian cancer	0.000739	0.0154	CbGeAlD
Fulvestrant—ESR2—uterine cervix—ovarian cancer	0.000734	0.0153	CbGeAlD
Fulvestrant—NR1H4—lymph node—ovarian cancer	0.0007	0.0146	CbGeAlD
Fulvestrant—ESR2—endometrium—ovarian cancer	0.000664	0.0139	CbGeAlD
Fulvestrant—ESR1—myometrium—ovarian cancer	0.000646	0.0135	CbGeAlD
Fulvestrant—ESR1—embryo—ovarian cancer	0.000621	0.013	CbGeAlD
Fulvestrant—ESR2—gonad—ovarian cancer	0.000616	0.0129	CbGeAlD
Fulvestrant—EPHX2—lymph node—ovarian cancer	0.000612	0.0128	CbGeAlD
Fulvestrant—ESR2—uterus—ovarian cancer	0.000612	0.0128	CbGeAlD
Fulvestrant—Estradiol—CYP1B1—ovarian cancer	0.000561	0.509	CrCbGaD
Fulvestrant—ESR2—female reproductive system—ovarian cancer	0.00055	0.0115	CbGeAlD
Fulvestrant—ESRRA—lymph node—ovarian cancer	0.000536	0.0112	CbGeAlD
Fulvestrant—ESR1—epithelium—ovarian cancer	0.000507	0.0106	CbGeAlD
Fulvestrant—ESR1—uterine cervix—ovarian cancer	0.000503	0.0105	CbGeAlD
Fulvestrant—ESR2—female gonad—ovarian cancer	0.0005	0.0104	CbGeAlD
Fulvestrant—ESR2—vagina—ovarian cancer	0.000497	0.0104	CbGeAlD
Fulvestrant—ESR1—decidua—ovarian cancer	0.000479	0.01	CbGeAlD
Fulvestrant—ESR1—endometrium—ovarian cancer	0.000455	0.00949	CbGeAlD
Fulvestrant—ESR2—testis—ovarian cancer	0.000444	0.00927	CbGeAlD
Fulvestrant—ESR1—gonad—ovarian cancer	0.000422	0.00881	CbGeAlD
Fulvestrant—ESR1—uterus—ovarian cancer	0.000419	0.00875	CbGeAlD
Fulvestrant—Estradiol—ESR1—ovarian cancer	0.000379	0.344	CrCbGaD
Fulvestrant—ESR1—female reproductive system—ovarian cancer	0.000377	0.00786	CbGeAlD
Fulvestrant—ESR1—female gonad—ovarian cancer	0.000343	0.00716	CbGeAlD
Fulvestrant—ESR1—vagina—ovarian cancer	0.000341	0.00711	CbGeAlD
Fulvestrant—ESR2—lymph node—ovarian cancer	0.000322	0.00672	CbGeAlD
Fulvestrant—ESR1—testis—ovarian cancer	0.000304	0.00635	CbGeAlD
Fulvestrant—ESR1—lymph node—ovarian cancer	0.00022	0.0046	CbGeAlD
Fulvestrant—CYP3A4—female reproductive system—ovarian cancer	0.00021	0.00439	CbGeAlD
Fulvestrant—Estradiol—ABCB1—ovarian cancer	0.000161	0.146	CrCbGaD
Fulvestrant—Diarrhoea—Chlorambucil—ovarian cancer	0.000131	0.00185	CcSEcCtD
Fulvestrant—Paraesthesia—Vinorelbine—ovarian cancer	0.000131	0.00185	CcSEcCtD
Fulvestrant—Infestation NOS—Docetaxel—ovarian cancer	0.000131	0.00184	CcSEcCtD
Fulvestrant—Infestation—Docetaxel—ovarian cancer	0.000131	0.00184	CcSEcCtD
Fulvestrant—Dyspnoea—Vinorelbine—ovarian cancer	0.00013	0.00184	CcSEcCtD
Fulvestrant—Hepatic failure—Epirubicin—ovarian cancer	0.000127	0.0018	CcSEcCtD
Fulvestrant—Decreased appetite—Vinorelbine—ovarian cancer	0.000127	0.00179	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000126	0.00178	CcSEcCtD
Fulvestrant—Fatigue—Vinorelbine—ovarian cancer	0.000126	0.00178	CcSEcCtD
Fulvestrant—Hypersensitivity—Topotecan—ovarian cancer	0.000126	0.00178	CcSEcCtD
Fulvestrant—Angiopathy—Paclitaxel—ovarian cancer	0.000126	0.00177	CcSEcCtD
Fulvestrant—Pain—Vinorelbine—ovarian cancer	0.000125	0.00176	CcSEcCtD
Fulvestrant—Constipation—Vinorelbine—ovarian cancer	0.000125	0.00176	CcSEcCtD
Fulvestrant—Immune system disorder—Paclitaxel—ovarian cancer	0.000125	0.00176	CcSEcCtD
Fulvestrant—Hepatobiliary disease—Docetaxel—ovarian cancer	0.000124	0.00174	CcSEcCtD
Fulvestrant—Hypersensitivity—Melphalan—ovarian cancer	0.000123	0.00174	CcSEcCtD
Fulvestrant—Asthenia—Topotecan—ovarian cancer	0.000123	0.00173	CcSEcCtD
Fulvestrant—Hot flush—Epirubicin—ovarian cancer	0.000122	0.00172	CcSEcCtD
Fulvestrant—Vomiting—Chlorambucil—ovarian cancer	0.000122	0.00172	CcSEcCtD
Fulvestrant—Menopausal symptoms—Epirubicin—ovarian cancer	0.000121	0.00171	CcSEcCtD
Fulvestrant—Pruritus—Topotecan—ovarian cancer	0.000121	0.00171	CcSEcCtD
Fulvestrant—Malnutrition—Paclitaxel—ovarian cancer	0.000121	0.0017	CcSEcCtD
Fulvestrant—Asthenia—Melphalan—ovarian cancer	0.00012	0.00169	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.00012	0.00169	CcSEcCtD
Fulvestrant—Pruritus—Melphalan—ovarian cancer	0.000119	0.00167	CcSEcCtD
Fulvestrant—Haemoglobin—Docetaxel—ovarian cancer	0.000118	0.00166	CcSEcCtD
Fulvestrant—Hepatic failure—Doxorubicin—ovarian cancer	0.000118	0.00166	CcSEcCtD
Fulvestrant—Haemorrhage—Docetaxel—ovarian cancer	0.000117	0.00165	CcSEcCtD
Fulvestrant—Hepatitis—Docetaxel—ovarian cancer	0.000117	0.00165	CcSEcCtD
Fulvestrant—Diarrhoea—Topotecan—ovarian cancer	0.000117	0.00165	CcSEcCtD
Fulvestrant—Back pain—Paclitaxel—ovarian cancer	0.000117	0.00164	CcSEcCtD
Fulvestrant—Pharyngitis—Docetaxel—ovarian cancer	0.000117	0.00164	CcSEcCtD
Fulvestrant—Urticaria—Vinorelbine—ovarian cancer	0.000116	0.00164	CcSEcCtD
Fulvestrant—Body temperature increased—Vinorelbine—ovarian cancer	0.000116	0.00163	CcSEcCtD
Fulvestrant—Abdominal pain—Vinorelbine—ovarian cancer	0.000116	0.00163	CcSEcCtD
Fulvestrant—Oedema peripheral—Docetaxel—ovarian cancer	0.000116	0.00163	CcSEcCtD
Fulvestrant—Connective tissue disorder—Docetaxel—ovarian cancer	0.000115	0.00163	CcSEcCtD
Fulvestrant—Diarrhoea—Melphalan—ovarian cancer	0.000115	0.00162	CcSEcCtD
Fulvestrant—Pain in extremity—Epirubicin—ovarian cancer	0.000114	0.00161	CcSEcCtD
Fulvestrant—Nausea—Chlorambucil—ovarian cancer	0.000114	0.00161	CcSEcCtD
Fulvestrant—Hot flush—Doxorubicin—ovarian cancer	0.000113	0.0016	CcSEcCtD
Fulvestrant—Dizziness—Topotecan—ovarian cancer	0.000113	0.00159	CcSEcCtD
Fulvestrant—Menopausal symptoms—Doxorubicin—ovarian cancer	0.000112	0.00158	CcSEcCtD
Fulvestrant—Anaemia—Paclitaxel—ovarian cancer	0.000111	0.00157	CcSEcCtD
Fulvestrant—Angioedema—Paclitaxel—ovarian cancer	0.00011	0.00155	CcSEcCtD
Fulvestrant—Vomiting—Topotecan—ovarian cancer	0.000109	0.00153	CcSEcCtD
Fulvestrant—Vertigo—Paclitaxel—ovarian cancer	0.000108	0.00153	CcSEcCtD
Fulvestrant—Leukopenia—Paclitaxel—ovarian cancer	0.000108	0.00152	CcSEcCtD
Fulvestrant—Rash—Topotecan—ovarian cancer	0.000108	0.00152	CcSEcCtD
Fulvestrant—Hypersensitivity—Vinorelbine—ovarian cancer	0.000108	0.00152	CcSEcCtD
Fulvestrant—Dermatitis—Topotecan—ovarian cancer	0.000108	0.00152	CcSEcCtD
Fulvestrant—Headache—Topotecan—ovarian cancer	0.000107	0.00151	CcSEcCtD
Fulvestrant—Angiopathy—Docetaxel—ovarian cancer	0.000107	0.0015	CcSEcCtD
Fulvestrant—Vomiting—Melphalan—ovarian cancer	0.000107	0.0015	CcSEcCtD
Fulvestrant—Immune system disorder—Docetaxel—ovarian cancer	0.000106	0.00149	CcSEcCtD
Fulvestrant—Pain in extremity—Doxorubicin—ovarian cancer	0.000106	0.00149	CcSEcCtD
Fulvestrant—Rash—Melphalan—ovarian cancer	0.000106	0.00149	CcSEcCtD
Fulvestrant—Dermatitis—Melphalan—ovarian cancer	0.000106	0.00149	CcSEcCtD
Fulvestrant—Cough—Paclitaxel—ovarian cancer	0.000105	0.00148	CcSEcCtD
Fulvestrant—Asthenia—Vinorelbine—ovarian cancer	0.000105	0.00148	CcSEcCtD
Fulvestrant—Pruritus—Vinorelbine—ovarian cancer	0.000104	0.00146	CcSEcCtD
Fulvestrant—Breast disorder—Epirubicin—ovarian cancer	0.000103	0.00146	CcSEcCtD
Fulvestrant—Arthralgia—Paclitaxel—ovarian cancer	0.000103	0.00145	CcSEcCtD
Fulvestrant—Chest pain—Paclitaxel—ovarian cancer	0.000103	0.00145	CcSEcCtD
Fulvestrant—Myalgia—Paclitaxel—ovarian cancer	0.000103	0.00145	CcSEcCtD
Fulvestrant—Anxiety—Paclitaxel—ovarian cancer	0.000102	0.00144	CcSEcCtD
Fulvestrant—Malnutrition—Docetaxel—ovarian cancer	0.000102	0.00144	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000102	0.00144	CcSEcCtD
Fulvestrant—Nausea—Topotecan—ovarian cancer	0.000102	0.00143	CcSEcCtD
Fulvestrant—Diarrhoea—Vinorelbine—ovarian cancer	0.0001	0.00141	CcSEcCtD
Fulvestrant—Nausea—Melphalan—ovarian cancer	9.95e-05	0.0014	CcSEcCtD
Fulvestrant—Influenza—Epirubicin—ovarian cancer	9.9e-05	0.00139	CcSEcCtD
Fulvestrant—Back pain—Docetaxel—ovarian cancer	9.89e-05	0.00139	CcSEcCtD
Fulvestrant—Infection—Paclitaxel—ovarian cancer	9.78e-05	0.00138	CcSEcCtD
Fulvestrant—Dizziness—Vinorelbine—ovarian cancer	9.68e-05	0.00136	CcSEcCtD
Fulvestrant—Nervous system disorder—Paclitaxel—ovarian cancer	9.65e-05	0.00136	CcSEcCtD
Fulvestrant—Breast disorder—Doxorubicin—ovarian cancer	9.57e-05	0.00135	CcSEcCtD
Fulvestrant—Skin disorder—Paclitaxel—ovarian cancer	9.56e-05	0.00135	CcSEcCtD
Fulvestrant—Hyperhidrosis—Paclitaxel—ovarian cancer	9.52e-05	0.00134	CcSEcCtD
Fulvestrant—Anaemia—Docetaxel—ovarian cancer	9.45e-05	0.00133	CcSEcCtD
Fulvestrant—Anorexia—Paclitaxel—ovarian cancer	9.38e-05	0.00132	CcSEcCtD
Fulvestrant—Vomiting—Vinorelbine—ovarian cancer	9.3e-05	0.00131	CcSEcCtD
Fulvestrant—Rash—Vinorelbine—ovarian cancer	9.23e-05	0.0013	CcSEcCtD
Fulvestrant—Dermatitis—Vinorelbine—ovarian cancer	9.22e-05	0.0013	CcSEcCtD
Fulvestrant—Headache—Vinorelbine—ovarian cancer	9.17e-05	0.00129	CcSEcCtD
Fulvestrant—Influenza—Doxorubicin—ovarian cancer	9.16e-05	0.00129	CcSEcCtD
Fulvestrant—Leukopenia—Docetaxel—ovarian cancer	9.15e-05	0.00129	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	8.97e-05	0.00126	CcSEcCtD
Fulvestrant—Cough—Docetaxel—ovarian cancer	8.92e-05	0.00126	CcSEcCtD
Fulvestrant—Insomnia—Paclitaxel—ovarian cancer	8.9e-05	0.00125	CcSEcCtD
Fulvestrant—Paraesthesia—Paclitaxel—ovarian cancer	8.84e-05	0.00125	CcSEcCtD
Fulvestrant—Infestation—Epirubicin—ovarian cancer	8.82e-05	0.00124	CcSEcCtD
Fulvestrant—Infestation NOS—Epirubicin—ovarian cancer	8.82e-05	0.00124	CcSEcCtD
Fulvestrant—Dyspnoea—Paclitaxel—ovarian cancer	8.78e-05	0.00124	CcSEcCtD
Fulvestrant—Arthralgia—Docetaxel—ovarian cancer	8.7e-05	0.00123	CcSEcCtD
Fulvestrant—Chest pain—Docetaxel—ovarian cancer	8.7e-05	0.00123	CcSEcCtD
Fulvestrant—Myalgia—Docetaxel—ovarian cancer	8.7e-05	0.00123	CcSEcCtD
Fulvestrant—Nausea—Vinorelbine—ovarian cancer	8.69e-05	0.00122	CcSEcCtD
Fulvestrant—Dyspepsia—Paclitaxel—ovarian cancer	8.66e-05	0.00122	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	8.64e-05	0.00122	CcSEcCtD
Fulvestrant—Urinary tract infection—Epirubicin—ovarian cancer	8.58e-05	0.00121	CcSEcCtD
Fulvestrant—Decreased appetite—Paclitaxel—ovarian cancer	8.56e-05	0.00121	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Paclitaxel—ovarian cancer	8.5e-05	0.0012	CcSEcCtD
Fulvestrant—Fatigue—Paclitaxel—ovarian cancer	8.49e-05	0.0012	CcSEcCtD
Fulvestrant—Sweating—Epirubicin—ovarian cancer	8.46e-05	0.00119	CcSEcCtD
Fulvestrant—Constipation—Paclitaxel—ovarian cancer	8.42e-05	0.00119	CcSEcCtD
Fulvestrant—Pain—Paclitaxel—ovarian cancer	8.42e-05	0.00119	CcSEcCtD
Fulvestrant—Hepatobiliary disease—Epirubicin—ovarian cancer	8.34e-05	0.00118	CcSEcCtD
Fulvestrant—Infection—Docetaxel—ovarian cancer	8.29e-05	0.00117	CcSEcCtD
Fulvestrant—Nervous system disorder—Docetaxel—ovarian cancer	8.18e-05	0.00115	CcSEcCtD
Fulvestrant—Infestation NOS—Doxorubicin—ovarian cancer	8.16e-05	0.00115	CcSEcCtD
Fulvestrant—Infestation—Doxorubicin—ovarian cancer	8.16e-05	0.00115	CcSEcCtD
Fulvestrant—Skin disorder—Docetaxel—ovarian cancer	8.1e-05	0.00114	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Paclitaxel—ovarian cancer	8.05e-05	0.00113	CcSEcCtD
Fulvestrant—Haemoglobin—Epirubicin—ovarian cancer	7.96e-05	0.00112	CcSEcCtD
Fulvestrant—Anorexia—Docetaxel—ovarian cancer	7.95e-05	0.00112	CcSEcCtD
Fulvestrant—Urinary tract infection—Doxorubicin—ovarian cancer	7.94e-05	0.00112	CcSEcCtD
Fulvestrant—Hepatitis—Epirubicin—ovarian cancer	7.92e-05	0.00112	CcSEcCtD
Fulvestrant—Haemorrhage—Epirubicin—ovarian cancer	7.92e-05	0.00112	CcSEcCtD
Fulvestrant—Pharyngitis—Epirubicin—ovarian cancer	7.86e-05	0.00111	CcSEcCtD
Fulvestrant—Sweating—Doxorubicin—ovarian cancer	7.83e-05	0.0011	CcSEcCtD
Fulvestrant—Urticaria—Paclitaxel—ovarian cancer	7.82e-05	0.0011	CcSEcCtD
Fulvestrant—Oedema peripheral—Epirubicin—ovarian cancer	7.8e-05	0.0011	CcSEcCtD
Fulvestrant—Connective tissue disorder—Epirubicin—ovarian cancer	7.78e-05	0.0011	CcSEcCtD
Fulvestrant—Body temperature increased—Paclitaxel—ovarian cancer	7.78e-05	0.0011	CcSEcCtD
Fulvestrant—Abdominal pain—Paclitaxel—ovarian cancer	7.78e-05	0.0011	CcSEcCtD
Fulvestrant—Hepatobiliary disease—Doxorubicin—ovarian cancer	7.72e-05	0.00109	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Docetaxel—ovarian cancer	7.6e-05	0.00107	CcSEcCtD
Fulvestrant—Insomnia—Docetaxel—ovarian cancer	7.55e-05	0.00106	CcSEcCtD
Fulvestrant—Paraesthesia—Docetaxel—ovarian cancer	7.49e-05	0.00106	CcSEcCtD
Fulvestrant—Dyspnoea—Docetaxel—ovarian cancer	7.44e-05	0.00105	CcSEcCtD
Fulvestrant—Haemoglobin—Doxorubicin—ovarian cancer	7.37e-05	0.00104	CcSEcCtD
Fulvestrant—Dyspepsia—Docetaxel—ovarian cancer	7.34e-05	0.00103	CcSEcCtD
Fulvestrant—Hepatitis—Doxorubicin—ovarian cancer	7.33e-05	0.00103	CcSEcCtD
Fulvestrant—Haemorrhage—Doxorubicin—ovarian cancer	7.33e-05	0.00103	CcSEcCtD
Fulvestrant—Pharyngitis—Doxorubicin—ovarian cancer	7.27e-05	0.00103	CcSEcCtD
Fulvestrant—Decreased appetite—Docetaxel—ovarian cancer	7.25e-05	0.00102	CcSEcCtD
Fulvestrant—Hypersensitivity—Paclitaxel—ovarian cancer	7.25e-05	0.00102	CcSEcCtD
Fulvestrant—Oedema peripheral—Doxorubicin—ovarian cancer	7.22e-05	0.00102	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Docetaxel—ovarian cancer	7.2e-05	0.00102	CcSEcCtD
Fulvestrant—Connective tissue disorder—Doxorubicin—ovarian cancer	7.2e-05	0.00101	CcSEcCtD
Fulvestrant—Fatigue—Docetaxel—ovarian cancer	7.19e-05	0.00101	CcSEcCtD
Fulvestrant—Angiopathy—Epirubicin—ovarian cancer	7.19e-05	0.00101	CcSEcCtD
Fulvestrant—Immune system disorder—Epirubicin—ovarian cancer	7.15e-05	0.00101	CcSEcCtD
Fulvestrant—Pain—Docetaxel—ovarian cancer	7.13e-05	0.00101	CcSEcCtD
Fulvestrant—Constipation—Docetaxel—ovarian cancer	7.13e-05	0.00101	CcSEcCtD
Fulvestrant—Asthenia—Paclitaxel—ovarian cancer	7.06e-05	0.000995	CcSEcCtD
Fulvestrant—Pruritus—Paclitaxel—ovarian cancer	6.96e-05	0.000981	CcSEcCtD
Fulvestrant—Malnutrition—Epirubicin—ovarian cancer	6.9e-05	0.000972	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Docetaxel—ovarian cancer	6.82e-05	0.000961	CcSEcCtD
Fulvestrant—Diarrhoea—Paclitaxel—ovarian cancer	6.73e-05	0.000949	CcSEcCtD
Fulvestrant—Back pain—Epirubicin—ovarian cancer	6.67e-05	0.00094	CcSEcCtD
Fulvestrant—Angiopathy—Doxorubicin—ovarian cancer	6.65e-05	0.000937	CcSEcCtD
Fulvestrant—Immune system disorder—Doxorubicin—ovarian cancer	6.62e-05	0.000933	CcSEcCtD
Fulvestrant—Body temperature increased—Docetaxel—ovarian cancer	6.6e-05	0.000929	CcSEcCtD
Fulvestrant—Abdominal pain—Docetaxel—ovarian cancer	6.6e-05	0.000929	CcSEcCtD
Fulvestrant—Dizziness—Paclitaxel—ovarian cancer	6.51e-05	0.000917	CcSEcCtD
Fulvestrant—Malnutrition—Doxorubicin—ovarian cancer	6.38e-05	0.000899	CcSEcCtD
Fulvestrant—Anaemia—Epirubicin—ovarian cancer	6.37e-05	0.000898	CcSEcCtD
Fulvestrant—Vomiting—Paclitaxel—ovarian cancer	6.26e-05	0.000882	CcSEcCtD
Fulvestrant—Rash—Paclitaxel—ovarian cancer	6.21e-05	0.000875	CcSEcCtD
Fulvestrant—Dermatitis—Paclitaxel—ovarian cancer	6.2e-05	0.000874	CcSEcCtD
Fulvestrant—Vertigo—Epirubicin—ovarian cancer	6.19e-05	0.000873	CcSEcCtD
Fulvestrant—Leukopenia—Epirubicin—ovarian cancer	6.17e-05	0.00087	CcSEcCtD
Fulvestrant—Back pain—Doxorubicin—ovarian cancer	6.17e-05	0.00087	CcSEcCtD
Fulvestrant—Headache—Paclitaxel—ovarian cancer	6.17e-05	0.000869	CcSEcCtD
Fulvestrant—Hypersensitivity—Docetaxel—ovarian cancer	6.15e-05	0.000866	CcSEcCtD
Fulvestrant—Cough—Epirubicin—ovarian cancer	6.02e-05	0.000848	CcSEcCtD
Fulvestrant—Asthenia—Docetaxel—ovarian cancer	5.99e-05	0.000844	CcSEcCtD
Fulvestrant—Pruritus—Docetaxel—ovarian cancer	5.9e-05	0.000832	CcSEcCtD
Fulvestrant—Anaemia—Doxorubicin—ovarian cancer	5.9e-05	0.000831	CcSEcCtD
Fulvestrant—Chest pain—Epirubicin—ovarian cancer	5.87e-05	0.000827	CcSEcCtD
Fulvestrant—Arthralgia—Epirubicin—ovarian cancer	5.87e-05	0.000827	CcSEcCtD
Fulvestrant—Myalgia—Epirubicin—ovarian cancer	5.87e-05	0.000827	CcSEcCtD
Fulvestrant—Anxiety—Epirubicin—ovarian cancer	5.85e-05	0.000824	CcSEcCtD
Fulvestrant—Nausea—Paclitaxel—ovarian cancer	5.85e-05	0.000824	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	5.83e-05	0.000822	CcSEcCtD
Fulvestrant—Vertigo—Doxorubicin—ovarian cancer	5.73e-05	0.000808	CcSEcCtD
Fulvestrant—Leukopenia—Doxorubicin—ovarian cancer	5.71e-05	0.000805	CcSEcCtD
Fulvestrant—Diarrhoea—Docetaxel—ovarian cancer	5.71e-05	0.000804	CcSEcCtD
Fulvestrant—Infection—Epirubicin—ovarian cancer	5.59e-05	0.000788	CcSEcCtD
Fulvestrant—Cough—Doxorubicin—ovarian cancer	5.57e-05	0.000785	CcSEcCtD
Fulvestrant—Nervous system disorder—Epirubicin—ovarian cancer	5.52e-05	0.000778	CcSEcCtD
Fulvestrant—Dizziness—Docetaxel—ovarian cancer	5.52e-05	0.000777	CcSEcCtD
Fulvestrant—Skin disorder—Epirubicin—ovarian cancer	5.47e-05	0.00077	CcSEcCtD
Fulvestrant—Hyperhidrosis—Epirubicin—ovarian cancer	5.44e-05	0.000767	CcSEcCtD
Fulvestrant—Arthralgia—Doxorubicin—ovarian cancer	5.43e-05	0.000765	CcSEcCtD
Fulvestrant—Myalgia—Doxorubicin—ovarian cancer	5.43e-05	0.000765	CcSEcCtD
Fulvestrant—Chest pain—Doxorubicin—ovarian cancer	5.43e-05	0.000765	CcSEcCtD
Fulvestrant—Anxiety—Doxorubicin—ovarian cancer	5.41e-05	0.000763	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	5.39e-05	0.00076	CcSEcCtD
Fulvestrant—Anorexia—Epirubicin—ovarian cancer	5.36e-05	0.000756	CcSEcCtD
Fulvestrant—Vomiting—Docetaxel—ovarian cancer	5.3e-05	0.000748	CcSEcCtD
Fulvestrant—Rash—Docetaxel—ovarian cancer	5.26e-05	0.000741	CcSEcCtD
Fulvestrant—Dermatitis—Docetaxel—ovarian cancer	5.26e-05	0.000741	CcSEcCtD
Fulvestrant—Headache—Docetaxel—ovarian cancer	5.23e-05	0.000737	CcSEcCtD
Fulvestrant—Infection—Doxorubicin—ovarian cancer	5.17e-05	0.000729	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Epirubicin—ovarian cancer	5.13e-05	0.000723	CcSEcCtD
Fulvestrant—Nervous system disorder—Doxorubicin—ovarian cancer	5.11e-05	0.00072	CcSEcCtD
Fulvestrant—Insomnia—Epirubicin—ovarian cancer	5.09e-05	0.000717	CcSEcCtD
Fulvestrant—Skin disorder—Doxorubicin—ovarian cancer	5.06e-05	0.000713	CcSEcCtD
Fulvestrant—Paraesthesia—Epirubicin—ovarian cancer	5.05e-05	0.000712	CcSEcCtD
Fulvestrant—Hyperhidrosis—Doxorubicin—ovarian cancer	5.03e-05	0.000709	CcSEcCtD
Fulvestrant—Dyspnoea—Epirubicin—ovarian cancer	5.02e-05	0.000707	CcSEcCtD
Fulvestrant—Anorexia—Doxorubicin—ovarian cancer	4.96e-05	0.000699	CcSEcCtD
Fulvestrant—Nausea—Docetaxel—ovarian cancer	4.96e-05	0.000698	CcSEcCtD
Fulvestrant—Dyspepsia—Epirubicin—ovarian cancer	4.95e-05	0.000698	CcSEcCtD
Fulvestrant—Decreased appetite—Epirubicin—ovarian cancer	4.89e-05	0.000689	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Epirubicin—ovarian cancer	4.86e-05	0.000685	CcSEcCtD
Fulvestrant—Fatigue—Epirubicin—ovarian cancer	4.85e-05	0.000684	CcSEcCtD
Fulvestrant—Constipation—Epirubicin—ovarian cancer	4.81e-05	0.000678	CcSEcCtD
Fulvestrant—Pain—Epirubicin—ovarian cancer	4.81e-05	0.000678	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	4.74e-05	0.000669	CcSEcCtD
Fulvestrant—Insomnia—Doxorubicin—ovarian cancer	4.71e-05	0.000664	CcSEcCtD
Fulvestrant—Paraesthesia—Doxorubicin—ovarian cancer	4.68e-05	0.000659	CcSEcCtD
Fulvestrant—Dyspnoea—Doxorubicin—ovarian cancer	4.64e-05	0.000654	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	4.63e-05	0.000898	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—VEGFA—ovarian cancer	4.62e-05	0.000896	CbGpPWpGaD
Fulvestrant—Gastrointestinal pain—Epirubicin—ovarian cancer	4.6e-05	0.000648	CcSEcCtD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	4.6e-05	0.000891	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—ABCB1—ovarian cancer	4.6e-05	0.000891	CbGpPWpGaD
Fulvestrant—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	4.6e-05	0.000891	CbGpPWpGaD
Fulvestrant—Dyspepsia—Doxorubicin—ovarian cancer	4.58e-05	0.000646	CcSEcCtD
Fulvestrant—ESR1—ATF-2 transcription factor network—MAPK1—ovarian cancer	4.57e-05	0.000885	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—PARP1—ovarian cancer	4.55e-05	0.000882	CbGpPWpGaD
Fulvestrant—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	4.54e-05	0.000879	CbGpPWpGaD
Fulvestrant—Decreased appetite—Doxorubicin—ovarian cancer	4.53e-05	0.000638	CcSEcCtD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	4.52e-05	0.000875	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	4.51e-05	0.000874	CbGpPWpGaD
Fulvestrant—Gastrointestinal disorder—Doxorubicin—ovarian cancer	4.5e-05	0.000633	CcSEcCtD
Fulvestrant—Fatigue—Doxorubicin—ovarian cancer	4.49e-05	0.000633	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—HRAS—ovarian cancer	4.48e-05	0.000867	CbGpPWpGaD
Fulvestrant—Urticaria—Epirubicin—ovarian cancer	4.47e-05	0.00063	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	4.47e-05	0.000865	CbGpPWpGaD
Fulvestrant—Pain—Doxorubicin—ovarian cancer	4.45e-05	0.000627	CcSEcCtD
Fulvestrant—Constipation—Doxorubicin—ovarian cancer	4.45e-05	0.000627	CcSEcCtD
Fulvestrant—Abdominal pain—Epirubicin—ovarian cancer	4.45e-05	0.000627	CcSEcCtD
Fulvestrant—Body temperature increased—Epirubicin—ovarian cancer	4.45e-05	0.000627	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—FASN—ovarian cancer	4.45e-05	0.000861	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—WDR77—ovarian cancer	4.43e-05	0.000858	CbGpPWpGaD
Fulvestrant—ESR1—Validated nuclear estrogen receptor alpha network—MYC—ovarian cancer	4.38e-05	0.000848	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—SLC5A5—ovarian cancer	4.37e-05	0.000847	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—YAP1—ovarian cancer	4.36e-05	0.000845	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	4.35e-05	0.000843	CbGpPWpGaD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—AKT1—ovarian cancer	4.33e-05	0.000839	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	4.31e-05	0.000836	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of Telomerase—MAPK3—ovarian cancer	4.29e-05	0.00083	CbGpPWpGaD
Fulvestrant—Gastrointestinal pain—Doxorubicin—ovarian cancer	4.26e-05	0.0006	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—SLC2A1—ovarian cancer	4.22e-05	0.000818	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of Telomerase—MYC—ovarian cancer	4.17e-05	0.000807	CbGpPWpGaD
Fulvestrant—NR1H4—Transmembrane transport of small molecules—ABCB1—ovarian cancer	4.16e-05	0.000806	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—STAT3—ovarian cancer	4.15e-05	0.000803	CbGpPWpGaD
Fulvestrant—Hypersensitivity—Epirubicin—ovarian cancer	4.15e-05	0.000584	CcSEcCtD
Fulvestrant—ESR1—Signaling by ERBB4—IL6ST—ovarian cancer	4.14e-05	0.000803	CbGpPWpGaD
Fulvestrant—Urticaria—Doxorubicin—ovarian cancer	4.14e-05	0.000583	CcSEcCtD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	4.14e-05	0.000801	CbGpPWpGaD
Fulvestrant—Abdominal pain—Doxorubicin—ovarian cancer	4.12e-05	0.00058	CcSEcCtD
Fulvestrant—Body temperature increased—Doxorubicin—ovarian cancer	4.12e-05	0.00058	CcSEcCtD
Fulvestrant—NR1H4—Gene Expression—YAP1—ovarian cancer	4.1e-05	0.000794	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of Telomerase—MAPK1—ovarian cancer	4.08e-05	0.00079	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of Telomerase—EGFR—ovarian cancer	4.08e-05	0.00079	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—MYC—ovarian cancer	4.07e-05	0.000789	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—CYP1B1—ovarian cancer	4.05e-05	0.000784	CbGpPWpGaD
Fulvestrant—Asthenia—Epirubicin—ovarian cancer	4.04e-05	0.000569	CcSEcCtD
Fulvestrant—Pruritus—Epirubicin—ovarian cancer	3.98e-05	0.000561	CcSEcCtD
Fulvestrant—NR1H4—Generic Transcription Pathway—ESR1—ovarian cancer	3.97e-05	0.000769	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—MAPK3—ovarian cancer	3.96e-05	0.000768	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	3.93e-05	0.000762	CbGpPWpGaD
Fulvestrant—Diarrhoea—Epirubicin—ovarian cancer	3.85e-05	0.000543	CcSEcCtD
Fulvestrant—Hypersensitivity—Doxorubicin—ovarian cancer	3.84e-05	0.000541	CcSEcCtD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	3.79e-05	0.000735	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—MAPK1—ovarian cancer	3.77e-05	0.00073	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—YAP1—ovarian cancer	3.74e-05	0.000724	CbGpPWpGaD
Fulvestrant—Asthenia—Doxorubicin—ovarian cancer	3.74e-05	0.000526	CcSEcCtD
Fulvestrant—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	3.73e-05	0.000722	CbGpPWpGaD
Fulvestrant—Dizziness—Epirubicin—ovarian cancer	3.72e-05	0.000524	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	3.72e-05	0.000721	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—PPP2R1A—ovarian cancer	3.69e-05	0.000715	CbGpPWpGaD
Fulvestrant—Pruritus—Doxorubicin—ovarian cancer	3.68e-05	0.000519	CcSEcCtD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—CDH1—ovarian cancer	3.68e-05	0.000713	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—MYC—ovarian cancer	3.62e-05	0.000702	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	3.62e-05	0.000701	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—PPP2R1A—ovarian cancer	3.59e-05	0.000696	CbGpPWpGaD
Fulvestrant—Vomiting—Epirubicin—ovarian cancer	3.58e-05	0.000504	CcSEcCtD
Fulvestrant—NR1H4—Gene Expression—PGR—ovarian cancer	3.58e-05	0.000693	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	3.57e-05	0.000692	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—YAP1—ovarian cancer	3.57e-05	0.000691	CbGpPWpGaD
Fulvestrant—Diarrhoea—Doxorubicin—ovarian cancer	3.56e-05	0.000502	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—FASN—ovarian cancer	3.55e-05	0.000688	CbGpPWpGaD
Fulvestrant—Rash—Epirubicin—ovarian cancer	3.55e-05	0.0005	CcSEcCtD
Fulvestrant—Dermatitis—Epirubicin—ovarian cancer	3.54e-05	0.0005	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	3.54e-05	0.000686	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	3.54e-05	0.000686	CbGpPWpGaD
Fulvestrant—Headache—Epirubicin—ovarian cancer	3.53e-05	0.000497	CcSEcCtD
Fulvestrant—ESR1—ATF-2 transcription factor network—IL6—ovarian cancer	3.51e-05	0.00068	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—PIK3CD—ovarian cancer	3.5e-05	0.000678	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—SLC5A5—ovarian cancer	3.5e-05	0.000677	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—TTF1—ovarian cancer	3.47e-05	0.000673	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	3.46e-05	0.000671	CbGpPWpGaD
Fulvestrant—ESR2—Generic Transcription Pathway—ESR1—ovarian cancer	3.46e-05	0.000669	CbGpPWpGaD
Fulvestrant—Dizziness—Doxorubicin—ovarian cancer	3.44e-05	0.000485	CcSEcCtD
Fulvestrant—ESR1—Signaling Pathways—HSD17B6—ovarian cancer	3.39e-05	0.000656	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—SLC2A1—ovarian cancer	3.38e-05	0.000654	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—TP53—ovarian cancer	3.34e-05	0.000648	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	3.34e-05	0.000648	CbGpPWpGaD
Fulvestrant—Nausea—Epirubicin—ovarian cancer	3.34e-05	0.000471	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—ABCB1—ovarian cancer	3.33e-05	0.000646	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—PARP1—ovarian cancer	3.33e-05	0.000644	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	3.32e-05	0.000642	CbGpPWpGaD
Fulvestrant—Vomiting—Doxorubicin—ovarian cancer	3.31e-05	0.000467	CcSEcCtD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	3.31e-05	0.00064	CbGpPWpGaD
Fulvestrant—Rash—Doxorubicin—ovarian cancer	3.28e-05	0.000463	CcSEcCtD
Fulvestrant—Dermatitis—Doxorubicin—ovarian cancer	3.28e-05	0.000462	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—TYMS—ovarian cancer	3.27e-05	0.000634	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—PGR—ovarian cancer	3.26e-05	0.000632	CbGpPWpGaD
Fulvestrant—Headache—Doxorubicin—ovarian cancer	3.26e-05	0.00046	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—CYP1B1—ovarian cancer	3.24e-05	0.000627	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—IL6—ovarian cancer	3.2e-05	0.00062	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—YAP1—ovarian cancer	3.19e-05	0.000617	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—NR5A1—ovarian cancer	3.15e-05	0.000611	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	3.15e-05	0.000611	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—PGR—ovarian cancer	3.12e-05	0.000604	CbGpPWpGaD
Fulvestrant—Nausea—Doxorubicin—ovarian cancer	3.09e-05	0.000436	CcSEcCtD
Fulvestrant—ESR1—Signaling by ERBB4—ERBB2—ovarian cancer	3.09e-05	0.000599	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	3.07e-05	0.000595	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—MTOR—ovarian cancer	3.07e-05	0.000594	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—IL6—ovarian cancer	3.06e-05	0.000593	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—MTOR—ovarian cancer	3.05e-05	0.000591	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—PIK3CB—ovarian cancer	3.05e-05	0.000591	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—PARP1—ovarian cancer	3.03e-05	0.000588	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—HRAS—ovarian cancer	3.03e-05	0.000586	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	2.97e-05	0.000576	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—PARP1—ovarian cancer	2.9e-05	0.000561	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of Telomerase—AKT1—ovarian cancer	2.89e-05	0.00056	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—DLC1—ovarian cancer	2.88e-05	0.000558	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PPP2R1A—ovarian cancer	2.87e-05	0.000556	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—CDKN1B—ovarian cancer	2.86e-05	0.000554	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.86e-05	0.000553	CbGpPWpGaD
Fulvestrant—ESRRA—Generic Transcription Pathway—MYC—ovarian cancer	2.82e-05	0.000547	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—CASP3—ovarian cancer	2.82e-05	0.000546	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.77e-05	0.000537	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—CCND1—ovarian cancer	2.74e-05	0.000532	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—CTNNB1—ovarian cancer	2.72e-05	0.000527	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—PPP2R1A—ovarian cancer	2.7e-05	0.000523	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—AKT1—ovarian cancer	2.67e-05	0.000518	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—ABCB1—ovarian cancer	2.67e-05	0.000516	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—PTEN—ovarian cancer	2.65e-05	0.000513	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—CAV1—ovarian cancer	2.64e-05	0.000511	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—PTEN—ovarian cancer	2.64e-05	0.000511	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—TYMS—ovarian cancer	2.62e-05	0.000507	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—ESR1—ovarian cancer	2.61e-05	0.000506	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—FASN—ovarian cancer	2.6e-05	0.000503	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	2.57e-05	0.000499	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—SLC5A5—ovarian cancer	2.55e-05	0.000495	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.52e-05	0.000488	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—AKT1—ovarian cancer	2.51e-05	0.000487	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	2.51e-05	0.000486	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—SLC2A1—ovarian cancer	2.47e-05	0.000478	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.42e-05	0.000468	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—PIK3CG—ovarian cancer	2.4e-05	0.000466	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—VEGFA—ovarian cancer	2.39e-05	0.000464	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	2.38e-05	0.000462	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—CYP1B1—ovarian cancer	2.37e-05	0.000458	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—NRAS—ovarian cancer	2.35e-05	0.000456	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—PPP2R1A—ovarian cancer	2.35e-05	0.000455	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—BCL9—ovarian cancer	2.35e-05	0.000455	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	2.34e-05	0.000453	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	2.27e-05	0.000441	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	2.25e-05	0.000436	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—MAPK3—ovarian cancer	2.25e-05	0.000436	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—MYC—ovarian cancer	2.2e-05	0.000427	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	2.2e-05	0.000425	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—MAPK1—ovarian cancer	2.15e-05	0.000417	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—EGFR—ovarian cancer	2.15e-05	0.000417	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—MAPK1—ovarian cancer	2.14e-05	0.000415	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—EGFR—ovarian cancer	2.14e-05	0.000415	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—PIK3CD—ovarian cancer	2.11e-05	0.000409	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—CAV1—ovarian cancer	2.11e-05	0.000409	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PPP2R1A—ovarian cancer	2.1e-05	0.000406	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.09e-05	0.000404	CbGpPWpGaD
Fulvestrant—NR1H4—Generic Transcription Pathway—MYC—ovarian cancer	2.06e-05	0.0004	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—KRAS—ovarian cancer	2.03e-05	0.000394	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—KRAS—ovarian cancer	2.02e-05	0.000392	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.02e-05	0.00039	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	1.98e-05	0.000384	CbGpPWpGaD
Fulvestrant—CYP3A4—Biological oxidations—CYP1B1—ovarian cancer	1.98e-05	0.000384	CbGpPWpGaD
Fulvestrant—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	1.95e-05	0.000378	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—ABCB1—ovarian cancer	1.95e-05	0.000377	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PIK3CG—ovarian cancer	1.92e-05	0.000372	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—TYMS—ovarian cancer	1.91e-05	0.000371	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—ESR1—ovarian cancer	1.91e-05	0.00037	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	1.88e-05	0.000363	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—PIK3CA—ovarian cancer	1.86e-05	0.00036	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—DOK1—ovarian cancer	1.85e-05	0.000359	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—PIK3CB—ovarian cancer	1.84e-05	0.000357	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	1.82e-05	0.000353	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—TP53—ovarian cancer	1.81e-05	0.00035	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—YAP1—ovarian cancer	1.8e-05	0.000349	CbGpPWpGaD
Fulvestrant—ESR2—Generic Transcription Pathway—MYC—ovarian cancer	1.8e-05	0.000348	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	1.78e-05	0.000346	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	1.78e-05	0.000346	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PPP1CC—ovarian cancer	1.74e-05	0.000338	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—HRAS—ovarian cancer	1.72e-05	0.000333	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PIK3CD—ovarian cancer	1.69e-05	0.000327	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	1.69e-05	0.000327	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—ESR1—ovarian cancer	1.66e-05	0.000322	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—IL6—ovarian cancer	1.65e-05	0.000319	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—PTEN—ovarian cancer	1.59e-05	0.000308	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—PGR—ovarian cancer	1.57e-05	0.000304	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	1.55e-05	0.0003	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—CAV1—ovarian cancer	1.54e-05	0.000299	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—AKT1—ovarian cancer	1.53e-05	0.000296	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—AKT1—ovarian cancer	1.52e-05	0.000294	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	1.5e-05	0.00029	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.47e-05	0.000285	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PIK3CB—ovarian cancer	1.47e-05	0.000285	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—PARP1—ovarian cancer	1.46e-05	0.000283	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PIK3CG—ovarian cancer	1.4e-05	0.000272	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—MAPK3—ovarian cancer	1.4e-05	0.000271	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—MYC—ovarian cancer	1.36e-05	0.000263	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—HDAC6—ovarian cancer	1.32e-05	0.000256	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PTEN—ovarian cancer	1.27e-05	0.000246	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	1.27e-05	0.000245	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PIK3CD—ovarian cancer	1.23e-05	0.000239	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—NME2—ovarian cancer	1.21e-05	0.000234	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—PPP2R1A—ovarian cancer	1.18e-05	0.00023	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—YAP1—ovarian cancer	1.17e-05	0.000227	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—XIAP—ovarian cancer	1.15e-05	0.000222	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—PIK3CA—ovarian cancer	1.12e-05	0.000217	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—SMARCA4—ovarian cancer	1.12e-05	0.000216	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—EREG—ovarian cancer	1.09e-05	0.000211	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PIK3CB—ovarian cancer	1.08e-05	0.000208	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—MAPK3—ovarian cancer	1.02e-05	0.000198	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PGR—ovarian cancer	1.02e-05	0.000198	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—MYC—ovarian cancer	9.94e-06	0.000192	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PARP1—ovarian cancer	9.5e-06	0.000184	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—AKT1—ovarian cancer	9.43e-06	0.000183	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PTEN—ovarian cancer	9.3e-06	0.00018	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—AKT1—ovarian cancer	9.17e-06	0.000178	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—MYC—ovarian cancer	9.06e-06	0.000176	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PIK3CA—ovarian cancer	8.97e-06	0.000174	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—MAPK3—ovarian cancer	8.9e-06	0.000172	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—MYC—ovarian cancer	8.65e-06	0.000168	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CYTB—ovarian cancer	7.78e-06	0.000151	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PPP2R1A—ovarian cancer	7.7e-06	0.000149	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—AKT1—ovarian cancer	7.33e-06	0.000142	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—AKT1—ovarian cancer	6.89e-06	0.000133	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PPP1CC—ovarian cancer	6.8e-06	0.000132	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—BRIP1—ovarian cancer	6.8e-06	0.000132	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PIK3CA—ovarian cancer	6.56e-06	0.000127	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TERT—ovarian cancer	6.12e-06	0.000119	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—AKT1—ovarian cancer	6e-06	0.000116	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CAV1—ovarian cancer	5.66e-06	0.00011	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—IL6ST—ovarian cancer	5.37e-06	0.000104	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—AKT1—ovarian cancer	5.36e-06	0.000104	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PIK3CG—ovarian cancer	5.16e-06	9.99e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—APC—ovarian cancer	5.16e-06	9.99e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—YAP1—ovarian cancer	4.56e-06	8.83e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PIK3CD—ovarian cancer	4.53e-06	8.78e-05	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—MAPK3—ovarian cancer	4.49e-06	8.69e-05	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—MYC—ovarian cancer	4.36e-06	8.45e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—ERBB2—ovarian cancer	4e-06	7.76e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PIK3CB—ovarian cancer	3.95e-06	7.65e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MTOR—ovarian cancer	3.95e-06	7.65e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CXCL8—ovarian cancer	3.8e-06	7.35e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—FASN—ovarian cancer	3.72e-06	7.2e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CDKN1B—ovarian cancer	3.71e-06	7.18e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—SLC5A5—ovarian cancer	3.66e-06	7.08e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CASP3—ovarian cancer	3.63e-06	7.04e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—IL2—ovarian cancer	3.63e-06	7.03e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CCND1—ovarian cancer	3.54e-06	6.85e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—SLC2A1—ovarian cancer	3.53e-06	6.84e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CTNNB1—ovarian cancer	3.5e-06	6.79e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MMP9—ovarian cancer	3.43e-06	6.65e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PTEN—ovarian cancer	3.41e-06	6.61e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CYP1B1—ovarian cancer	3.39e-06	6.56e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—VEGFA—ovarian cancer	3.08e-06	5.97e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—STAT3—ovarian cancer	3.05e-06	5.91e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—NRAS—ovarian cancer	3.05e-06	5.9e-05	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—AKT1—ovarian cancer	3.03e-06	5.86e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	3e-06	5.82e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MAPK3—ovarian cancer	2.92e-06	5.65e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MYC—ovarian cancer	2.84e-06	5.5e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—ABCB1—ovarian cancer	2.79e-06	5.4e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MAPK1—ovarian cancer	2.78e-06	5.38e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—EGFR—ovarian cancer	2.77e-06	5.38e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—TYMS—ovarian cancer	2.74e-06	5.31e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—KRAS—ovarian cancer	2.62e-06	5.08e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PIK3CA—ovarian cancer	2.41e-06	4.67e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TP53—ovarian cancer	2.33e-06	4.51e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—HRAS—ovarian cancer	2.23e-06	4.32e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CAV1—ovarian cancer	2.21e-06	4.27e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—IL6—ovarian cancer	2.13e-06	4.13e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PIK3CG—ovarian cancer	2.01e-06	3.89e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—AKT1—ovarian cancer	1.97e-06	3.81e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PIK3CD—ovarian cancer	1.77e-06	3.42e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PIK3CB—ovarian cancer	1.54e-06	2.98e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PTEN—ovarian cancer	1.33e-06	2.58e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PIK3CA—ovarian cancer	9.39e-07	1.82e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—AKT1—ovarian cancer	7.67e-07	1.49e-05	CbGpPWpGaD
